🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

842 results for “Eli” Clear

  1. Placebo to match LY, Muvalaplin

    Eli Lilly Co.

    Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  2. Placebo to match LY, PEMBROLIZUMAB , DURVALUMAB

    Eli Lilly Co.

    Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. Placebo to match LY, Retatrutide, Retatrutide, Retatrutide, Retatrutide, Retatrutide

    Eli Lilly Co.

    Overweight, Chronic Low Back Pain (CLBP), Obesity

    phase 3 small molecule active

    1 trial

  4. Placebo to match LY3527723, Placebo to match LY3527723, SELPERCATINIB, SELPERCATINIB

    Eli Lilly Co.

    RET fusion-Positive NSCLC

    phase 3 small molecule active

    1 trial

  5. Placebo to match LY3537982, PEMBROLIZUMAB , PEMETREXED , CARBOPLATIN , CISPLATIN

    Eli Lilly Co.

    Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  6. Placebo to match abemaciclib, Verzenios 50 mg film-coated tablets, FULVESTRANT

    Eli Lilly Co.

    Breast Neoplasm, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  7. Placebo to match ly, Eloralintide, Eloralintide, Eloralintide, Eloralintide

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  8. Placebo to match ly, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

    Eli Lilly Co.

    Urinary Incontinence, Stress

    phase 3 small molecule active

    1 trial

  9. Plasma exchange

    Ultragenyx UK Limited

    Acute Disseminated Encephalomyelitis

    phase 3 other active

    1 trial

  10. Pozelimab

    Regeneron UK Limited

    Age-related Macular Degeneration (AMD)

    phase 3 small molecule active

    1 trial

  11. Pozelimab

    Regeneron UK Limited

    CD55-deficient Protein-losing Enteropathy

    phase 3 small molecule completed

    1 trial

  12. Pozelimab

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    4 trials

  13. Pozelimab + Cemdisiran

    Regeneron UK Limited

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  14. Pozelimab, Cemdisiran

    Pharma Mar S.A.

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  15. RAMUCIRUMAB, ERLOTINIB

    Eli Lilly Co.

    Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. REGN7508, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, Eliquis 2.5 mg film-coated tablets, SODIUM CHLORIDE, REGN7508

    Pharma Mar S.A.

    Thromboembolic disease

    phase 3 small molecule active

    1 trial

  17. RHB-105

    RedHill Biopharma

    Helicobacter Pylori Infection

    phase 3 small molecule completed

    1 trial

  18. Remternetug, Placebo to match LY

    Eli Lilly Co.

    Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  19. Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS)

    Pari Pharma GmbH

    Remyelination in Multiple Sclerosis

    phase 3 other active

    1 trial

  20. Retatrutide, Tirzepatide, Retatrutide, Tirzepatide, Tirzepatide, Tirzepatide, Retatrutide, Retatrutide, Retatrutide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  21. Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s

    Incyte Biosciences Distribution B.V.

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  22. Revlimid 2.5 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 25 mg hard capsules, SOLDESAM 0,2% gocce orali, soluzione, Kyprolis 60 mg powder for solution for infusion

    Fondazione Telethon ETS

    PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT

    phase 3 small molecule active

    1 trial

  23. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Pharma Mar S.A.

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  24. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Roche Registration Limited

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources